All In Biotech

Drug Trial Radar · NCT06040086

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (MIRANDA)

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,454 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,454

Actual

Start

Sep 22, 2023

Primary completion

Mar 6, 2026

Study completion May 22, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with symptomatic COPD with a history of ≥ 2 moderate or ≥ 1 severe exacerbations of COPD in the 12 months prior to enrolment. Participants should be receiving optimised treatment with inhaled maintenance therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) throughout at least the last 3 months prior to enrolment.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • PlaceboDrug

    Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study.

  • TozorakimabDrug

    Administered subcutaneously tozorakimab and placebo throughout the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.Time frame: Over 52 weeks

Locations

368 sites in 29 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Decatur, Alabama

  • Research Site

    Sheffield, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Yuma, Arizona

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

  • Research Site

    San Francisco, California

  • Research Site

    Westminster, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Boulder, Colorado

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Boynton Beach, Florida

  • Research Site

    Cape Coral, Florida

  • Research Site

    Lakeland, Florida

  • Research Site

    Lakeland, Florida

  • Research Site

    Naples, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Ormond Beach, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Lithonia, Georgia

  • Research Site

    Champaign, Illinois

  • Research Site

    Chicago, Illinois

  • Research Site

    Chicago, Illinois

  • Research Site

    Andover, Kansas

  • Research Site

    Bowling Green, Kentucky

  • Research Site

    Lexington, Kentucky

  • Research Site

    Towson, Maryland

  • Research Site

    Detroit, Michigan

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Chesterfield, Missouri

  • Research Site

    Chesterfield, Missouri

  • Research Site

    Hannibal, Missouri

  • Research Site

    Papillion, Nebraska

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Toms River, New Jersey

  • Research Site

    The Bronx, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Greenville, North Carolina

Showing 40 of 368 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.